TB-500 and Thymosin Beta-4: What the Evidence Actually Covers
TB-500 is often discussed alongside BPC-157 for soft-tissue recovery. A 2026 scoping review shows where that evidence base actually sits — and where it doesn't.
TB-500 is a synthetic fragment of thymosin beta-4 (Tβ4), a naturally occurring protein involved in actin regulation — the cytoskeletal protein that controls how cells move and change shape. Because cell migration is central to wound repair, Tβ4 and its fragments have been studied for decades as candidates for tissue regeneration.
A 2026 scoping review covering the Tβ4/TB-500 literature identified the bulk of the evidence in two areas: angiogenesis (new blood vessel formation) and cell migration, particularly endothelial migration, tube formation, and VEGF signaling. Preclinical models spanned rat bone healing, diabetic rat tendon and wound models, mouse dystrophy and burn models, rat ligament injury, and even limb regeneration studies in Xenopus frogs. Most of that work — about 27.5% of identified studies — concentrated on wound, skin, and soft-tissue outcomes, with another 21.3% in vascular and endothelial settings.
Musculoskeletal applications — the tendon and ligament repair use case TB-500 is most marketed for — turn out to be the thinnest part of the evidence base. The same scoping review found no human interventional studies of administered Tβ4 or TB-500 in tendon, ligament, muscle, bone, cartilage, or spine indications. The human evidence that does exist is elsewhere: a small randomized, placebo-controlled Phase 1 dose study in healthy volunteers (Annals of the New York Academy of Sciences, 2010) established basic safety and pharmacokinetics, and a Phase II trial tested a Tβ4 ophthalmic solution for dry eye (Clinical Ophthalmology, 2015) — neither addresses the tendon/ligament claim the compound is usually sold on.
The regulatory picture reinforces the caution: the FDA lists the Tβ4 fragment (LKKTETQ, the sequence TB-500 is built around) among bulk drug substances that may present significant safety risks in compounding, citing limited human exposure and safety data. The World Anti-Doping Agency separately classifies Tβ4 and its derivatives as prohibited substances in competitive sport.
The honest summary: a genuinely large and mechanistically coherent animal literature, concentrated in wound and vascular biology rather than the tendon/ligament use case it's usually sold for, and no completed human trials in the applications people actually discuss it for. That's a meaningfully different evidence picture than the marketing copy usually implies.